24
RANDOMIZED PHASE III TRIAL COMPARING FOLFIRINOX (5FU/leucovorin, irinotecan and oxaliplatin) VS GEMCITABINE AS FIRST-LINE TREATMENT FOR METASTATIC PANCREATIC ADENOCARCINOMA Prodige 4 - ACCORD 11/0402 trial: final results T. Conroy , F. Desseigne, M. Ychou, M. Ducreux, O. Bouché, R. Guimbaud, Y. Bécouarn, C. Montoto-Grillot, S. Gourgou-Bourgade, A. Adenis, FNCLCC-FFCD Prodige group Centre Alexis Vautrin, Nancy; Centre Léon Bérard, Lyon; Centre Val d'Aurelle, Montpellier; Institut Gustave Roussy, Villejuif; Centre Hospitalier R. Debré, Reims; Institut Claudius Regaud, Toulouse; Institut Bergonié, Bordeaux; Fédération Nationale des Centres de Lutte Contre le Cancer - BECT, Paris; Centre Oscar Lambret, Lille; FRANCE

RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Embed Size (px)

Citation preview

Page 1: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

RANDOMIZED PHASE III TRIAL COMPARING FOLFIRINOX (5FU/leucovorin, irinotecan and oxaliplatin)

VS GEMCITABINE AS FIRST-LINE TREATMENT FOR METASTATIC PANCREATIC ADENOCARCINOMA

Prodige 4 - ACCORD 11/0402 trial: final results

T. Conroy , F. Desseigne, M. Ychou, M. Ducreux, O. Bouché, R. Guimbaud, Y. Bécouarn, C. Montoto-Grillot, S. Go urgou-Bourgade,

A. Adenis, FNCLCC-FFCD Prodige group

Centre Alexis Vautrin, Nancy; Centre Léon Bérard, L yon; Centre Val d'Aurelle, Montpellier; Institut Gustave Roussy, Villejuif; Centre Hospital ier R. Debré, Reims;

Institut Claudius Regaud, Toulouse; Institut Bergon ié, Bordeaux; Fédération Nationale des Centres de Lutte Contre le Cancer - BECT, Paris;

Centre Oscar Lambret, Lille; FRANCE

Page 2: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Background

� Metastatic pancreatic ductal adenocarcinoma:

� incurable disease

� few good treatment options

� Gemcitabine as single agent:

� cornerstone of treatment

� median survival: 6 to 7 mo.

� Gemcitabine-based combinations generally failed to increase survival

� Some trials suggested a possible benefit from combinati onchemotherapy in good performance status patients

Page 3: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Background

� Folfirinox regimen assessed in a phase II study (n=35)

� promising regimen in good PS patients with M1 disease

� median survival of 9.5 months

� A phase II-III randomized study comparing Folfirinox regime n to gemcitabine alone was launched

� Results of phase II randomized study step (n=88) were pres entedduring ASCO 2007:

� 31.8% RR in the Folfirinox arm vs

� 11.4% in the gemcitabine arm

� Due to these encouraging interim results, the trial contin uedas a phase III study.

Conroy T et al. J Clin Oncol 2005;23:1228-36Ychou M et al. J Clin Oncol 2007;25:18S:201s

Page 4: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Prodige 4 - ACCORD 11 trial design

Stratification :

� center� performance status: 0 versus 1� location of the tumor: head versus other location of the primary

Metastaticpancreaticcancer

RANDOMIZE

Folfirinox

Gemcitabine

6 months of chemotherapyrecommended

CT scans: obtained

every 2 months

for both arms:

Page 5: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Inclusion Criteria

� Histologically/cytologically confirmed pancreatic ade nocarcinoma

� ECOG performance status of 0 or 1

� Measurable metastases

� No prior cytotoxic chemotherapy

� No prior abdominal radiotherapy

� Age 18-75 years

� Adequate hematopoietic, hepatic and renal function

� Bilirubin < 1.5 UNL

� No unstable angina or myocardial infarction within 12 months before entry

� Written informed consent

Page 6: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Non Inclusion Criteria

� Non ductal pancreatic cancer (endocrine, acinar cell…)

� Adenocarcinoma of the ampulla of Vater

� Unresectable locally advanced pancreatic cancer withou t distant metastases (stage III)

� Central Nervous System metastases

� Chronic diarrhea

� Other previous or concomitant malignant disease

Page 7: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Experimental Arm: FOLFIRINOX

Oxaliplatin 85 mg/m 2 over 2 hours,Leucovorin 400 mg/m 2 over 2 hours,Irinotecan 180 mg/m 2 in 90 mn infusion,5-FU 400 mg/m 2 bolus, 5-FU 2400 mg/m 2 on 46-h infusion.

1 cycle = 14 days

1 h 30

2 h

2 h 46 h

Oxaliplatin85 mg/m 2

Irinotecan180 mg/m 2

Leucovorin400 mg/m 2

Continuous 5-FU 2.400 mg/m 2

Bolus 5-FU 400 mg/m 2

q2wks

Page 8: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Reference Arm: Gemcitabine

Gemcitabine1000 mg/m 2 over 30 minutes

given weekly x 7/8and then weekly x 3/4

1 cycle = 14 days

Burris AH et al. J Clin Oncol 1997;15:2403-13

Page 9: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Endpoints

� Secondary:

� objective response rate (RECIST)� toxicity (NCI-CTC version 3.0 grading)� progression-free survival (PFS)� quality of life (EORTC QLQ-C30 v 3.0)

� Primary: overall survival

Page 10: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Statistical considerations

� Hypothesis:

Study designed to have 80% power to detect an incre ase in median overall survival from 7 to 10 months (HR 0.70)

� Sample size:

� 360 patients required to reach 250 events for final analysis, based on the use of the log-rank test with a two-sided signif icance level of 5%

� Planned interim analysis after observation of 167 e vents

� Intent to treat analysis (ITT)

Page 11: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Trial progress

� Recruitment: January 2005-October 2009

� IDMC meeting, 30 September, 2009: Preplanned interim analysis after 192 events

Recommendation to stop accrual:preplanned primary objective met (p <0.001)

� Final accrual of 342 patients

� Current analysis database frozen: 16 April, 2010

� Number of deaths observed: 273 (73.4% of the sample size)

Page 12: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Flow Chart

Folfirinox Gemcitabine Total

Total randomized 171 171 342

Did not fulfill all eligibility criteria

8* 7* 15 (4%)

Untreated patients 4 2 6 (2%)

ITT population 171 171 342 (100%)

Safety population 167 169 336 (98%)

*Folfirinox arm : 2 patients > 76 years; one patient PS=2; 5 patients with high bilirubin, high creatinine or low platelets

*Gemcitabine arm: 7 patients with high bilirubin, high creatinine or low platelets

Page 13: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Patients characteristics

CharacteristicFolfirinox

N=171Gemcitabine

N=171p

Median age (yrs)[range]

61[25-76]

61[34-75]

NS

Sex MaleFemale

106 (62%)65 (38%)

105 (61.4%)66 (38.6%) NS

Baseline PS 012

64 (37.4%)106 (62.0%)

1 (0.6%)

66 (38.6%)105 (61.4%)

0 (0.0%)NS

Location of primary HeadOther

62 (36.3%)109 (63.7%)

60 (35.1%)111 (64.9%) NS

Page 14: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Disease characteristics

CharacteristicFolfirinox

N=171Gemcitabine

N=171p

Synchronous metastasesMetachronous metastases

156 (91.2%)15 (8.8%)

161 (94.2%)10 (5.8%)

NSNS

Median nr. of involved sitesCA19-9 ≥≥≥≥ 59 ULN

2 (1-6)68 (41.5%)

2 (1-6)77 (46.7%)

NSNS

Measurable site

LiverPancreasNodesLungsPeritoneal

149 (88.2%)89 (52.7%)48 (28.4%)33 (19.5%)33 (19.5%)

150 (87.7%)91 (53.2%)39 (22.8%)49 (28.7%)32 (18.7%)

NSNSNS

0.049NS

Page 15: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Safety: hematological AEs

AE, % per patient

FolfirinoxN=167

GemcitabineN=169

p

All Grade 3/4 All Grade 3/4 Grade 3/4

Neutropenia 79.9 45.7 54.8 18.7 0.0001

Febrile Neutropenia 7.2 2.4 0.6 0.009

Anemia 90.4 7.8 94.6 5.4 NS

Thrombocytopenia 75.2 9.1 54.8 2.4 0.008

5.4

42.5 % of the pts received G-CSF in the F arm vs 5.3% in the G armOne toxic death occurred in each armAE, adverse event

Page 16: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Safety: main non-hematological AEs

AE, % per patientFolfirinox N=167 Gemcitabine N=169

pAll Grade 3/4 All Grade 3/4

Infection without neutropenia

6 1.2 7.1 1.8 NS

Peripheral neuropathy 70.5 9 0.6 0 0.0001

Vomiting 61.4 14.5 43.2 4.7 0.002

Fatigue 87.3 23.2 78.7 14.2 0.036

Diarrhea 73.3 12.7 30.8 1.2 0.0001

Alopecia (grade 2) 32.5 (11.4) 3.0 (0.6) 0.0001

ALT 64.8 7.3 83.8 0.002218.618.6

Page 17: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Objective Response Rate

FolfirinoxN=171

GemcitabineN=171

p

Complete response 0.6% 0%

Partial response 31% 9.4% 0.0001

CR/PR 95% CI [24.7-39.1] [5.9-15.4]

Stable disease 38.6% 41.5%

Disease controlCR+PR+SD

70.2% 50.9% 0.0003

Progression 15.2% 34.5%

Not assessed 14.6% 14.6%

Median durationof response

5.9 mo. 4 mo. ns

Page 18: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Progression-Free Survival

0.00

0.25

0.50

0.75

1.00P

roba

bilit

y

171 121 85 42 17 7 4 1 1 0 0 0 0Folfirinox171 88 26 8 5 2 0 0 0 0 0 0 0Gemcitabine

Number at risk

0 3 6 9 12 15 18 21 24 27 30 33 36Months

Gemcitabine Folfirinox

p<0.0001

HR=0.47 : 95%CI [0.37-0.59]

Median PFS Folfirinox: 6.4 mo. Median PFS Gemcitabine: 3.3 mo

Page 19: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Overall Survival

FolfirinoxN=171

GemcitabineN=171

p HR

Median survival[CI 95%]

11.1 mo.[ 9 - 13.1]

6.8 mo.[ 5.5 - 7.6]

<0.0001 0.57

1-yr. survival 48.4% 20.6%

18-mo. survival 18.6% 6%

Median follow up: 26.6 months [95% CI: 20.5 – 44.9]

Page 20: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Overall Survival

0.00

0.25

0.50

0.75

1.00P

roba

bilit

y

171146116 81 62 34 20 13 9 5 3 2 2Folfirinox171134 89 48 28 14 7 6 3 3 2 2 2Gemcitabine

Number at risk

0 3 6 9 12 15 18 21 24 27 30 33 36Months

Gemcitabine Folfirinox

Stratified Log-rank test, p<0.0001

HR=0.57 : 95%CI [0.45-0.73]

Page 21: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Time to definitive QoL degradation

0.00

0.25

0.50

0.75

1.00P

roba

bilit

y

163 89 35 13 4 1 1Folfirinox157 53 9 1 0 0 0Gemcitabine

Number at risk

0 3 6 9 12 15 18Months

Gemcitabine Folfirinox

p=.001

Kaplan-Meier estimation for TUDD ofGlobal health status/QoL (MCID 10 points)

Page 22: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Conclusions

� Folfirinox treatment resulted in a higher frequency of gr. 3/4 febrile neutropenia (5.4%), emphasizing the need for vigilant patient selection, education, monitoring, and active managem ent

� Folfirinox regimen:� is more toxic but has manageable toxicity

� Significantly improves PFS: reduced risk of disease progression by 53%

� Delays QoL degradation

� Significantly improves overall survival (HR 0.57, p <0.0001) : median survival 11.1 mo.

� Folfirinox recommended as new worldwide standard of c are for patients with metastatic pancreatic cancer, bilirubin <1.5 UNL and PS 0-1

� This combination will be tested in adjuvant setting

Page 23: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Thank you !

� Trial supported by two Clinical Research Hospital P rogram grants (PHRC 2004 and 2007) from the French Ministry of He alth.

� sanofi-aventis and Pfizer for oxaliplatin and irino tecan supply.� Grants from Amgen and from the French National Leag ue Against Cancer.

� To our very brave and wonderful patients and their families who trust us.

� To enthusiastic CRA (M. Torres-Macque, F. Nait-Atma ne, S. Prigent, S. Levêque), Anne-Chantal Le Gall, and safety departmen t (J. Genève, MD, and collaborators) who also trust us... but check e verything!

� To our remarkably efficient data-managers (A. Pommie r and S. Louveau)

� To all investigators of the 48 active centers, thei r pharmacists and research staff for quick accrual and excellent qual ity of the data

� To very talented physicians and statisticians who h elped to plan and execute this trial

� To IDMC members (B. Asselain, MD; E. François, MD; Pr E. Gamelin, MD; Pr C. Louvet, MD) for their sound advice.

Page 24: RANDOMIZED PHASE III TRIAL COMPARING … · KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO

Acknowledgements

All investigators : Dr Françoise DESSEIGNE, Dr Christelle de la FOUCHARDIERE Centre Léon Bérard LYON ; Pr. Marc YCHOU Centre Val d'Aurelle MONTPELLIER ; Pr. Michel DUCREUX Institut Gustave Roussy VILLEJUIF ; Pr Olivier BOUCHE Centre Hospitalier R. Debré REIMS ; Pr Rosine GUIMBAUD Institut Claudius Regaud TOULOUSE ; Dr Yves BECOUARN Institut Bergonié BORDEAUX ; Pr. Antoine ADENIS Centre Oscar Lambret LILLE; Pr. Jean-Luc RAOUL Centre Eugène Marquis RENNES ; Pr Philippe ROUGIER Hôpital Ambroise Paré BOULOGNE-BILLANCOURT ; Dr Jaafar BENNOUNA Centre René Gauducheau NANTES - St HERBLAIN ; Dr Marie-Christine KAMINSKY, Dr Ivan KRAKOWSKI, Centre Alexis Vautrin, NANCY; Dr Faiza KHEMISSA-AKOUZ Centre hospitalier M. Joffre PERPIGNAN ; Dr Denis PÈRE-VERGÉ Hôpital de la Croix-Rousse LYON ; Dr Catherine DELBALDO CHU Henri Mondor CRETEIL ; Pr Bruno CHAUFFERT Centre François Leclerc DIJON; Pr Pierre MICHEL CHU ROUEN ; Dr Thierry N'GUYEN CHU Jean Minjoz BESANCON ; Dr Jean-Louis JOUVE CHU du Bocage DIJON ; Dr Gilles PIOT CMC Les Ormeaux Vauban LE HAVRE ; Dr Mohammed GASMI Hôpital Nord MARSEILLE ; Dr Patrick TEXEREAU Centre Hospitalier Général MONT DE MARSAN ; Dr Christian BOREL Centre Paul Strauss STRASBOURG ; Dr Frédérique CVITKOVIC Centre René Huguenin SAINT-CLOUD ; Dr Marie-Pierre GALAIS Centre François Baclesse CAEN ; Dr Thierry LECOMTE Centre hospitalier TOURS ; Dr Jean-Paul LAGASSE CHR ORLEANS ; Pr Françoise MORNEX Centre Hospitalier Lyon Sud PIERRE-BENITE ; Dr Dominique ARSENE Centre hospitalier universitaire CAEN ; Dr Yves RINALDI Hôpital Ambroise Paré MARSEILLE ; Dr Gaël DEPLANQUE Hôpital Saint Joseph PARIS ; Pr Thomas APARICIO Hopital Bichat-Claude Bernard PARIS; Dr Vanessa PALASCAK-JUIF Hôpital Hautepierre STRASBOURG ; Dr Gaëtan DES GUETZ Hôpital Avicenne BOBIGNY ; Dr Cédric LECAILLE Polyclinique Bordeaux Nord Aquitaine BORDEAUX ; Dr Catherine LOMBARD-BOHAS Hôpital Edouard Herriot LYON; Dr Pierre-Luc ETIENNE Clinique Armoricaine de Radiologie SAINT-BRIEUC ; Dr Laurent CHARNEAU Hôpital Duchenne BOULOGNE sur MER ; Dr Serge FRATTE CH de Belfort-Montbéliard BELFORT ; Dr Gilles BREYSACHER Hôpitaux Civils de Colmar COLMAR ; Dr Ahmed AZZEDINE Centre Hospitalier Henri Duffaut AVIGNON ; Dr Jean-Paul JOLY CHU Amiens Picardie AMIENS ; Dr Laurent POINCLOUX CHU Hôtel Dieu CLERMONT-FERRAND ; Dr Anne-Marie QUEUNIET CHI Elbeuf-Louviers-Val de Reuil St AUBIN lès ELBEUF ; Dr Jean-Frédéric BLANC Hôpital Saint André BORDEAUX ; Dr Olivier DUBROEUCQ Institut Jean Godinot REIMS ; Dr Christophe DESAUW Hôpital Saint Vincent de Paul LILLE ; Pr Jean-François SEITZ CHU de la Timone MARSEILLE; Dr Christian PLATINI Hôpital Bon Secours METZ. FRANCE